HighTower Advisors
HALO icon

HighTower Advisors’s Halozyme HALO Stock Holding History

HighTower Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,000
Closed -$1K – 2322
2017
Q3 		$1K Buy
+1,000
New +$13.5K ﹤0.01% 2207

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

HighTower Advisors's HALO Position: Q2 2026 in Review

HighTower Advisors reduced its Halozyme (HALO) stake by 16% in Q2 2026, selling an estimated $192K and leaving 15,024 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2137.

HighTower Advisors first reported a position in HALO in Q2 2013 and has held it in 49 quarters since. The position peaked at $5.14M in Q4 2022. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • HighTower Advisors held 15,024 shares of Halozyme worth $1.18M as of Q2 2026.
  • HighTower Advisors sold 2,817 Halozyme shares in Q2 2026, an estimated $192K.
  • Halozyme made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2137 holding.
  • HighTower Advisors first reported a position in Halozyme in Q2 2013 and has held it in 49 quarters since.
  • HighTower Advisors's Halozyme position peaked at $5.14M in Q4 2022.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.